SCHEMBL4064708

SCHEMBL4064708

CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@@H](O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 1.00
DGKA P23743 1/20 0.84
KDM4E B2RXH2 1/20 0.68
DUSP3 P51452 1/20 0.68
MEN1 O00255 1/20 0.68
KMT2A Q03164 1/20 0.68
LMNA P02545 1/20 0.68
MGLL Q99685 1/20 0.66
ALDH1A1 P00352 2/20 0.64
MAPT P10636 2/20 0.64
CNR1 P21554 2/20 0.64
HPGD P15428 1/20 0.64
CNR2 P34972 1/20 0.64
SELP P16109 1/20 0.64
THRB P10828 1/20 0.60
PRKCE Q02156 1/20 0.60
PRKCQ Q04759 1/20 0.60
PRKCD Q05655 1/20 0.60
PRKCA P17252 1/20 0.60
LPAR1 Q92633 3/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119943 1.00 FAAH (1.00) FAAHDGKAKDM4EDUSP3MEN1
SCHEMBL1133785 1.00 FAAH (1.00) FAAHDGKAKDM4EDUSP3MEN1
SCHEMBL28701704 0.97 FAAH (0.95) FAAHDGKAKDM4EDUSP3MEN1
Glyceryl Monolinoleate SCHEMBL154133 0.96 FAAH (0.92) FAAHDGKAKDM4EDUSP3MEN1
Glyceryl Monolinoleate SCHEMBL4350267 0.96 FAAH (0.92) FAAHDGKAKDM4EDUSP3MEN1
Glyceryl Monolinoleate SCHEMBL6371582 0.96 FAAH (0.92) FAAHDGKAKDM4EDUSP3MEN1
Glyceryl Monolinoleate SCHEMBL8536841 0.96 FAAH (0.92) FAAHDGKAKDM4EDUSP3MEN1
Glyceryl Monolinoleate SCHEMBL19564919 0.96 FAAH (0.92) FAAHDGKAKDM4EDUSP3MEN1
Glyceryl Monolinoleate SCHEMBL29943084 0.96 FAAH (0.92) FAAHDGKAKDM4EDUSP3MEN1
SCHEMBL29376457 0.96 FAAH (0.92) FAAHDGKAKDM4EDUSP3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119984322-A Emergency evacuation path planning method, program, equipment and storage medium considering dynamic inclination of passenger ship 哈尔滨工程大学 2025-05-13 CN claimed
CN-119916017-A Microfluidic chip for realizing differential counting of white blood cells and inflammation detection and use method 重庆医科大学绍兴柯桥医学检验技术研究中心 2025-05-02 CN claimed
CN-118996722-A Preparation method of silver nanoparticle modified double-layer carbon fiber membrane structure 天津工业大学 2024-11-22 CN claimed
CN-118722791-A Intelligent adjustment method, equipment, medium and product under sudden large passenger flow condition 北京交通大学 2024-10-01 CN claimed
CN-116092840-B Preparation method and application of ternary nano composite electrode material 华北水利水电大学 2024-05-31 CN claimed
WO-2024092556-A1 ELECTROCHEMILUMINESCENT IMMUNOMAGNETIC CHIP, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 深圳先进技术研究院 2024-05-10 WO claimed
CN-117990760-A Electrochemiluminescence magnetic immunity chip and preparation method and application thereof 深圳先进技术研究院 2024-05-07 CN claimed
CN-117952054-A Optimization method, equipment and medium for battery SOC of energy storage system 四川欣智造科技有限公司 2024-04-30 CN claimed
CN-116092840-A Preparation method and application of ternary nano composite electrode material 华北水利水电大学 2023-05-09 CN claimed
US-20230012268-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2023-01-12 US claimed
CN-115563754-A IGBT module aging characteristic decoupling parameter monitoring method based on temperature characteristic 西南交通大学 2023-01-03 CN claimed
CN-115083654-A Conductive paste and ceramic electronic component 株式会社村田制作所 2022-09-20 CN claimed
EP-4017486-A1 COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF Buzzelet Development And Technologies Ltd (IL) 2022-06-29 EP claimed
US-20220168246-A1 COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD (IL) 2022-06-02 US claimed
WO-2021117016-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INFLAMMATION WITH STEROIDS AND A MODULATOR BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) 2021-06-17 WO claimed
WO-2021033149-A1 COMPOSITONS FOR THE TREATMENT OF A CONDITION CHARACTERIZED BY ANANDAMIDE DEFICIENCY AND USES THEREOF BUZZELET DEVELOPMENT AND TECHNOLOGIES LTD. (IL) 2021-02-25 WO claimed
WO-2020137172-A1 METHOD FOR DIAGNOSING INTERSTITIAL CYSTITIS 公立大学法人奈良県立医科大学 2020-07-02 WO claimed
US-12599679-B2 Circular RNA compositions ORNA THERAPEUTICS, INC. (US) 2026-04-14 US disclosed
WO-2003008632-A1 FATTY ACID CONJUGATION AS A METHOD FOR SCREENING OF POTENTIALLY BIOACTIVE SUBSTANCES HOEGESTAETT EDWARD (SE) 2003-01-30 WO disclosed
WO-2003007875-A2 COMPOUNDS WITH ANALGESIC, ANTIPYRETIC AND/OR ANTI-INFLAMMATORY ACTIVITY HOEGESTAETT EDWARD (SE) 2003-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12599679-B2 Circular RNA compositions BCL6, BCL9, BCL6B FAAH 3674/4885DGKA 2612/4885KDM4E 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.